Skip to main content

Table 3 Characteristics of the thrombotic profile of healthy subjects

From: Development of a perfusion chamber assay to study in real time the kinetics of thrombosis and the antithrombotic characteristics of antiplatelet drugs

Parameters

 

Baseline

Clopidogrel

Clopidogrel + ASA

ASA

Max. Peak (pixels/μm2)

M ± sem median

800 ± 51 797

516 ± 48** 526

263 ± 53***,†, ‡ 243

484 ± 67* 460

Time to the peak (sec)

M ± sem Median

240 240

239 ± 1 240

203 ± 12*, † 208

234 ± 6 240

Slope before peak

M ± sem Median

4.3 ± 0.3 4.3

2.7 ± 0.2** 2.7

1.6 ± 0.2***,†, ‡ 1.6

2.7 ± 0.4 2.65

Slope after peak

M ± sem median

NA

1 out of 8# −0.18

5 out of 8# −1.2 ± 0.8

2 out of 8# −0.5 ± 0.4

Thrombus volume (μm3/μm2)

M ± sem

37 ± 5.2

25.8 ± 3.7

5.4 ± 0.5

22.1 ± 4.8

  1. Healthy subjects were evaluated at baseline, following clopidogrel (75 mg/d for 14 days), clopidogrel (75 mg/d for an additional 7 days) + aspirin (325 mg/d for 7 days), then aspirin (325 mg/day for 14 days) therapies. M (mean), *, **, *** ; P < 0.05, P < 0.01, P < 0.0001 vs baseline, respectively. †, P < 0.05 vs clopidogrel. ‡, P < 0.001 vs aspirin. Blood perfusion of 250 seconds; # indicates number of curves with reversal. Thrombus volume (μm3/μm2) was evaluated by computer assisted morphometry analysis of cross-sections cut perpendicularly to the blood flow at 8 mm from the proximal end of the capillary.